1. Cuneo RC, Salomon F, Sönksen PH. The growth hormone deficiency syndrome in adults. Clin Endocrinol 1992, 37, 387-397.

2. De Boer H, Blok G-J, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews 1995, 16, 63-86.

3. Carroll PV, Christ ER et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A Review. J Clin Endocrinol Metab 1998, 83,382-395.

4. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Quarterly Journal of Medicine 1988, 262, 145-160.

5. Rosén T, Bengtsson B-Å. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336, 285-8.

6. Bülow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 1997, 46, 75-81.

7. Tomlinson JW, Holden N, Hills RK, Clayton RN, Sheppard MC, Stewart PM. Association between premature mortality and hypopituitarism. Lancet 2001, 357, 425-31.

8. Markussis V, Beshyah SA, Fischer C, Sharp P, Nicolaides AN, Johnson DG. Detection of premature atherosclerosis by high resolution ultrasonography in symptom free hypopituitary adults. Lancet 1992, 340, 1188-92.

9. Fowelin J, Attrall S, Lager I, Bengtsson B-Å. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 1993, 42, 1443-7.

10. Johansson J-O, Landin K, Tengboru L, Rosén T, Bengtsson B-Å. High fibrinogen and plasminogen activator inhibitor activity in growth hormone deficient adults. Arterioscler Thromb 1994, 14, 434-7.

11. Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA, Cunningham JC. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995, 80, 153-9.

12. Capaldo B, Patti L, Oliverio U, Longobardi S, Pardo F, Vitali F, Fazio S, di Reller F, Bindi B, Lombardi G, Sacca L. Increased arterial intima-media thickness in childhood onset growth hormone deficiency. J Clin Endocrinol Metab 1997, 82, 1378-81.

13. Abs R, Bengtsson B-Å, Hernberg-Ståhl E, Monson JP, Tauber J-P, Wilton P, Wüster C on behalf of the KIMS Study Group. GH replacement in 1034 GH deficient adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol 1999, 50,703-713.

14. Florakis D, Hung V, Kaltsas G, Coyte D, Jenkins PJ, Chew SL, Grossman AB, Besser GM, Monson JP. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement: a two year study. Clin Endocrinol 2000, 53, 453-459.

15. Bengtsson B-Å, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Ståhl E, Westberg B, Wilton P, Wüster C. The effects of treatment and the individual responsiveness to GH replacement therapy in 665 GH-deficient adults. J Clin Endocrinol Metab 1999, 84, 3929-3935.

16. Gibney J, Wallace JD, Spinks T et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999, 84, 2596-2602.

17. Hoffman DM, O'Sullivan AJ, Baxter RC, Ho KY. Diagnosis of growth hormone deficiency in adults. Lancet 1994, 343 1064-8.

18. Thorner MO, Bengtsson B-Å, Ho KKY, Albertsson-Wikland KM, Christiansen JS, Faglia G, Irie M, Isaksson O, Ranke M, Rosenfeld R, Shalet S, Takano K, Van der Veen EA, Weissberger AJ. The diagnosis of growth hormone deficiency in adults: a consensus statement. J Clin Endocrinol Metab 1995, 3097-3098.

19. Rahim A, Toogood AA, Shalet SM. The assessment of growth hormone status in normal young adult males using a variety of provocative agents. Clin Endocrinol 1996, 45, 557-62.

20. Toogood AA, O'Neill PA, Shalet SM. Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab 1996, 81, 460-465.

21. Toogood AA, Beardwell CG, Shalet SM. The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism. Clin Endocrinol 1994, 41, 511-516.

22. Wirén L, Bengtsson B-Å, Johannsson G - Beneficial effects of long term GH replacement therapy on quality of life in adults with GH deficiency. Clin Endocrinol 1998, 48 613-620.

23. Drake WM, Rodriguez-Arnao J, Weaver JU, James I, Coyte D, Spector T, Besser GM, Monson JP. The influence of gender on the short and long term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults - a five year study. Clin Endocrinol 2001, 54, 525-532.

24. Gelding SV, Taylor NF, Wood PJ, Noonan K, Weaver JU, Wood DF, Monson JP. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11*-hydroxysteroid dehydrogenase activity. Clin Endocrinol 1998, 48, 153-162.

25. Wüster C, Abs R, Bengtsson B-Å, Bennmarker H, Feldt-Rasmussen U, Hernberg-Ståhl E, Monson JP, Westberg B, Wilton P. The influence of growth hormone (GH) deficiency, GH replacement therapy and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Min Res 2001, 16, 398-405.

26. Rosén T, Bengtsson B-Å. Increased fracture frequency in adult patients with hypopituitarism and growth hormone deficiency. Eur J Endocrinol 1997, 137, 240-245.

27. Weaver JU, Monson JP, Noonan K, Price C, Edwards A, Evans KA, James I, Cunningham J. The effects of low dose recombinant human growth hormone replacement on indices of bone remodelling and bone mineral density in hypopituitary growth hormone deficient adults. Endocrinol Metab 1996, 3, 55-61.

28. Johannsson G, Rosen T, Bosaeus I, Sjostrom L, Bengtsson B-Å. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult onset GH deficiency. J Clin Endocrinol Metab. 1996, 81, 2865-7.

29. Holmes SJ, Whitehouse RW, Swindell R, Economou G, Adams JE, Shalet SM. Efffect of growth hormone on bone mass in adults with adult onset growth hormone deficiency. Clin Endocrinol 1995, 42, 627-633.

30. Drake WM, Coyte D, Camacho-Hübner C, Jivanji NM, Kaltsas G, Wood DF, Trainer P, Grossman AB, Besser GM, Monson JP. Optimising growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 1999, 83, 3913-3919.

31. Murray RD, Skillicorn CJ, Howell SJ, Lissett CA, Rahim A, Shalet SM. Dose titration and patient selection increases the efficacy of GH replacement in severely GHD adults. Clin Endocrinol 1999, 50, 749-757.

32. Baum HBA, Katznelson L, Sherman JC et al. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult onset GH deficiency. J Clin Endocrinol Metab 1998, 83, 3184-3189.

33. Monson JP, Abs R, Bengtsson B-Å, Feldt-Rasmussen U, Wilton P. National differences in baseline characteristics and response to GH replacement in hypopituitary patients in KIMS. Endocrine Abstracts, (2001), 1, P122.

34. Olivecrona H, Ericsson S, Berglund L, Angelin B. Increased concentrations of serum lipoprotein(a) in response to growth hormone treatment B Med J 1993, 306, 1726-7.

35. Drake WM, Howell SJ, Monson JP, Shalet SM. Optimising GH therapy in adults and children. Endocrine Reviews 2001, 22, 425-450.

36. Monson JP, Abs R, Bengtsson B-Å, Bennmarker H, Feldt-Rasmussen U, Hernberg-Ståhl E, Thorén M, Westberg B, Wilton P, Wüster C. Growth hormone deficiency and replacement in elderly hypopituitary adults. Clin Endocrinol 2000, 53, 281-289.

36a. Frajese V, Drake WM, Laureiro R, Evanson J, Coyte D, Grossman AB, Besser GM, Monson JP. Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long term growth hormone replacement therapy. J Clin Endocrinol Metab (2001), 86, 5172-5175.

37. Fernholm R, Bramnert M, Hägg E, Hilding A, Baylink DJ, Mohan S, Thorén M. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab 2000, 85, 4104-4112.

38. Vahl N, Juul A, Jørgensen JOL, Ørskov H, Skakkebæk N, Christiansen JS. Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. J Clin Endocrinol Metab 2000, 85, 1874-1881.

39. Carroll PV, Drake WM, Maher KT, Metcalfe KA, Shaw NJ, Dunger DB, Cheetham TD, Camacho-Hübner C, Savage MO, Monson JP. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH-deficiency at completion of linear growth. J Clin Endocrinol Metab (2004), 89, 3890-3895.

40. Drake WM, Carroll PV, Maher KT, Metcalfe KA, Shaw NJ, Camacho-Hübner C, Dunger DB, Cheetham TD, Savage MO, Monson JP. Cessation of growth hormone therapy at final height limits the attainment of peak bone mass in adolescent growth hormone deficient patients. J Clin Endocrinol Metab (2003), 88, 1658-1663.

41. Hernberg-Ståhl E, Luger A, Abs R, Bengtsson B-Å, Feldt-Rasmussen U, Westberg B, Wilton P, Monson JP. Healthcare consumption decreases in parallel with improvements in quality of life during growth hormone (GH) replacement in hypopituitary adults with GH deficiency. J Clin Endocrinol Metab 2001, 86, 5277-5281.

42. Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M. Consensus statement on the management of the growth hormone treated adolescent in the transition to adult care. Eur J Endocrinol (2005), 152, 165-170.